TD Cowen raises Fortrea stock price target on margin outlook

TD Cowen raised its price target for Fortrea (NASDAQ:FTRE) to $26 from $23, citing improved margin outlook and WWCT acquisition. Shares are down 10.66% this week but up 103% year-over-year. Q3 2026 results missed estimates, but margins and cash flow improved, leading to raised 2026 guidance. Analysts from Jefferies and Truist also updated their price targets.

Original reporting
Published Nov 2, 2026, 10:00 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 2, 2026, 10:09 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefEarnings
Primary signal
$FTRE
Bullish
high confidence
Mentioned
$FTRE
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$FTREBullishMed
01

Why it matters

Analyst upgrades reflect confidence in margin expansion despite revenue shortfall.

02

Market read

New analyst price targets and guidance revisions provide fresh trading signals for FTRE.

03

What to watch

Potential headwinds from slower biotech spending and competitive pricing pressure.

Relevance 7/10Novelty 7/10Timing: today

Background

Fortrea reported Q3 2026 results that missed revenue and EPS expectations but showed better margins and cash flow.

Company-level read

Ticker impact

$FTREBullishHigh confidence
Context

TD Cowen raised its price target on Fortrea to $26 from $23, citing improved margins and the pending WWCT acquisition.

Expected impact

upward pressure as investors price in higher margins and acquisition synergies

Evidence & confidence

The new target reflects expectations of margin expansion and incremental benefit from the WWCT deal, which could lift the stock.

Market effects

Boosts sentiment for contract research organizations and CRO sector.

Positive impact on US biotech service providers.

Limited to U.S. markets; no immediate global ripple.

Counterpoint

The margin outlook may be overstated if WWCT integration faces delays.

Key entities

  • Fortrea Holdings Inc.

    Contract research organization serving pharma and biotech.

  • TD Cowen

    Raised price target to $26 based on margin outlook.

Related articles

$FTREMed

Truist raises Fortrea stock price target to $29 on margin outlook

Truist Securities raised its price target on Fortrea (NASDAQ:FTRE) to $29 from $26, maintaining a Buy rating. The stock trades at $23.14 with a $2.23B market cap. Fortrea reported a TTM book-to-bill ratio of 1.12x, below expectations, and expects Q4 adjusted EBITDA of $50M with a 7.5% margin, down from Q3. The company cited fewer working days and investments for the decline, but noted six consecutive quarters of margin upside and improving biotech demand.

$FTREMed

Fortrea Holdings Inc (FTRE) (Q3 2026) Earnings Call Highlights: Backlog Cleanup

Fortrea Holdings (FTRE) reported a $558M backlog adjustment, not impacting near-term revenue. Q4 EBITDA guidance was lowered due to fewer working days and IT investment. Gross margins improved from portfolio mix and efficiencies. CEO Anshul Thakral and CFO Jason Knobloch discussed growth strategies, including acquisitions like Worldwide Clinical Trials, and market recovery trends in biotech and biopharma. The company aims for mid-teens EBITDA margins and sees increasing RFP activity.

$FTREHighAI 8/10

Fortrea (FTRE) Q3 2026 Earnings Call Transcript

Fortrea (FTRE) reported Q3 2026 revenue of $691.5M, adjusted EBITDA of $58M, and a book-to-bill ratio of 1.12x. The company raised full-year guidance and completed an acquisition to expand its clinical pharmacology capacity. Fortrea's strategy focuses on revenue growth and margin expansion through commercial, operational, and financial excellence.

$FTREHighAI 8/10

What Fortrea (FTRE) Said on Its Q3 Earnings Call

Fortrea (FTRE) reported Q3 net income of $0.6M, up from a loss of $15.9M YoY. Adjusted net income was $27.9M, and adjusted EPS was $0.28. Operating cash flow improved to $60.8M. The company acquired Early Phase Services, expanding its clinical pharmacology network. Fortrea raised its 2026 revenue guidance to $2.665B-$2.690B and adjusted EBITDA to $210M-$218M. Management expects biotech and biopharma demand recovery.

$FTREHighAI 8/10

Fortrea Q3 2026 slides: EBITDA rises 14% as revenue falls short

Fortrea Holdings (FTRE) reported Q3 2026 revenue of $691.5M, down 1.4% YoY, missing estimates by $200.83M. Adjusted EBITDA rose 14.4% to $58.0M, with margins expanding to 8.4%. EPS missed by 55.6%, and the stock fell 11% premarket. Management raised full-year guidance but warned of Q4 revenue decline. The company acquired Worldwide Clinical Trials’ Early Phase Services for $45M, improving cash flow and liquidity.